Journey Medical reports Emrosi sales up 84% in third quarter of 2026
The dermatology company said Emrosi revenue climbed to $9.0 million while cash fell to $22.3 million, with the vendor dispute payout weighing on quarterly costs.
Journey Medical Corporation reported financial results for the third quarter ended September 30, 2026, in a release dated November 12, 2026. The revenue increase was driven by continued commercial demand momentum for Emrosi, which generated revenues of $9.0 million for the quarter ended September 30, 2026.1 Emrosi total prescriptions were approximately 40,000 for the third quarter of 2026.1
CEO Claude Maraoui said third quarter sales of Emrosi, the company's oral rosacea treatment, increased by 84% compared to the prior-year period, driven by growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans, and the number of unique prescribers writing for Emrosi increased again during the third quarter1. He added that the company's recently expanded sales force and increasing formulary additions with national health plans are expected to facilitate further adoption and market penetration1.
Total revenues were $19.0 million for the third quarter of 2026, an 8% increase from $17.6 million for the third quarter of 2025.1 SG&A rose by $0.5 million from the prior-year quarter, primarily due to a one-time expense of $1.7 million recognized upon resolution of a dispute with a former vendor, offset by a reduction in launch-related spending for Emrosi.1
On cash, the company said at September 30, 2026, it had $22.3 million in cash and cash equivalents, compared to $24.1 million at December 31, 2025.1 Maraoui said building on this progress and with over $22 million in cash, the company believes it is well-positioned to advance its mission of delivering value to dermatology customers and their patients while building long-term shareholder value.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.